Bang YJ et al. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: Primary analysis of JAVELIN Gastric 300. Ann Oncol 2018;29(10):2052-60. Abstract
Bang YJ et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687-97. Abstract
Catenacci DVT et al. Margetuximab plus pembrolizumab for previously treated, HER2-positive GEA (CP-MGAH22-05): A single-arm, phase 1b-2 trial. Lancet Oncology 2020;21(8):1066-76. Abstract
Catenacci DVT et al. Keeping checkpoint inhibitors in check. JAMA Netw Open 2019;2(5):e192546. Abstract
Chao J et al. Pembrolizumab in microsatellite instability-high advanced gastric/gastroesophageal junction cancer by line of therapy. Gastrointestinal Cancers Symposium 2020;Abstract 430.
Fuchs CS et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018;4(5):e180013. Abstract
Guimbaud R et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: A French intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) study. J Clin Oncol 2014;32(31):3520-6. Abstract
Kang YK et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390(10111):2461-71. Abstract
Kojima T et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol 2020;JCO2001888. Abstract
Kulangara K et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med 2019;143(3):330-7. Abstract
Le DT et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 2017;357(6349):409-13. Abstract
Lorenzen S et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel — Results from the phase II RAMIRIS Study of the AIO. ASCO 2020;Abstract 4514.
Shitara K et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: The KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol 2020;6(10):1571-80. Abstract
Shitara K et al. Trifluridine/tipiracil v placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2018;19(11):1437-48. Abstract